Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Meeting ReportASPET 2023 Annual Meeting Abstract - Central Nervous System Pharmacology - Neuropharmacology

Pharmacology of Memory Dysfunction in Alzheimer’s Disease (AD)

Marcia Ratner and David H. Farb
Journal of Pharmacology and Experimental Therapeutics June 2023, 385 (S3) 70; DOI: https://doi.org/10.1124/jpet.122.286940
Marcia Ratner
1Boston Univ School of Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David H. Farb
1Boston Univ School of Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Abstract ID 28694

Poster Board 70

The biological basis for memory continues to be actively investigated yet, as contrasted with cardiovascular pharmacology, an overarching pharmacological theory for the modulation of memory in healthy and diseased states remains largely unknown. To address this need for developing a platform for the interrogation of memory by probe drugs, we have focused on developing a paradigm for within subject interrogation of memory circuitry in vivo in awake ambulating animals as a basis for future discovery in a precision medicine approach to neurotherapeutics.

The hippocampal trisynaptic circuit (HTC) is formed by synapses between neurons in the entorhinal cortex (EC) synapsing on dentate granule cells (DC) that synapse upon pyramidal cells in the CA3 pyramidal neurons (Ca3 Pyr), which then synapse upon CA1 pyramidal neurons (CA1 Pyr): EC > DC > CA3 Pyr > CA1 PyR which is recognized as a core module in mammalian memory systems function. Disorders of aging such as mild cognitive impairment and AD are associated with HTC hyperactivity (Wilson et al., 2006; Yassa et al., 2010; Baker et al., 2015; Robitsek et al., 2015; Sosulinaet al., 2021). We demonstrated that acute systemic administration of low dose levetiracetam + valproic acid reduced HTC hyperactivity and increased the spatial information content encoded by HTC place cells (Robitsek et al., 2015). We have also shown that the dose-dependent ripple band response to administration of an orally bioavailable negative allosteric modulator of alpha5-type GABA-A receptors (alpha 5IA) is attenuated or eliminated in awake immobile TgF344-AD rats with elevated plasma AB42 and AB40 (Ratner et al., 2021).

Here, we ask whether Abeta42 that is produced in a transgenic rat model of AD (TgF344-AD) disrupts synchronously firing of subsets of CA1 PyR that comprise sharp wave ripples (SPW-Rs ) at 140 - 200 Hz. SPW-Rs are likely a functional elementary process in memory consolidation (Buzsaki 2015). Epsilon band (90 to 130 Hz) oscillations are smaller in amplitude than SPW-Rs and both emanate from CA3 Pyr oscillations. The boundary between these two frequency bands is defined by a characteristic dip between 130 and 150 Hz in power spectral density plots, surrounded by distinct peaks at 170–180 and 110 Hz. We have shown that this type of synchronous high frequency circuitry activity is disrupted in awake immobile TgF344-AD rats (Ratner et al., 2021).

We now show that administration of alpha5IA differentially modulates these two high frequency bands. In WT F344 CA1, alpha5IA dramatically potentiates SPW-Rs but has little effect on epsilon. Moreover, in TgF344-AD rats, where alpha5IA now fails to enhance the SPW-Rs, epsilon is largely unaffected by the overexpression of Abeta 42 and 40 and its sensitivity to alpha 5IA is not measurable in this respect like the ripple band. These observations suggest alpha-5 subunit-containing GABAA receptors, which are highly expressed in CA1 Pyr neurons play a role SPW-R modulation but not high frequency oscillations in the adjacent epsilon band. The results demonstrate that alpha5IA modulation can be used to differentiate between high frequency oscillations in the ripple band from those in the epsilon band. Further research will explore the relevance of this preferential modulatory effect in terms of the behaviorally demonstrated nootropic effects of alpha 5IA.

David H Farb was supported by National Institute on Aging

(R21AG056947, P01AG9973).

Marcia H. Ratner was supported by National Institute on Aging

(T32AG00115).

  • Copyright © 2023 by The American Society for Pharmacology and Experimental Therapeutics
Previous
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 385 (S3)
Journal of Pharmacology and Experimental Therapeutics
Vol. 385, Issue S3
1 Jun 2023
  • Complete Issue (PDF)
  • Table of Contents
  • Table of Contents (PDF)
  • Complete Issue (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Pharmacology of Memory Dysfunction in Alzheimer’s Disease (AD)
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Meeting ReportASPET 2023 Annual Meeting Abstract - Central Nervous System Pharmacology - Neuropharmacology

Pharmacology of Memory Dysfunction in Alzheimer’s Disease (AD)

Marcia Ratner and David H. Farb
Journal of Pharmacology and Experimental Therapeutics June 1, 2023, 385 (S3) 70; DOI: https://doi.org/10.1124/jpet.122.286940

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Meeting ReportASPET 2023 Annual Meeting Abstract - Central Nervous System Pharmacology - Neuropharmacology

Pharmacology of Memory Dysfunction in Alzheimer’s Disease (AD)

Marcia Ratner and David H. Farb
Journal of Pharmacology and Experimental Therapeutics June 1, 2023, 385 (S3) 70; DOI: https://doi.org/10.1124/jpet.122.286940
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Development of a Mouse Model to Study Alcohol Withdrawal-Induced Allodynia
  • Butyrate Prevents Opioid Induced Peripheral Hypersensitivity via a Gut Dependent Mechanism
  • Regulation of cAMP Signaling by Endothelin-A Receptor Antagonist, BQ123 in Morphine Tolerance in SH-SY5Y Human Neuroblastoma Cells
Show more ASPET 2023 Annual Meeting Abstract - Central Nervous System Pharmacology - Neuropharmacology

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics